Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)
This is a randomized, open-label, multicenter, phase III study comparing anthracyclines followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer.

Patients with stage II/III operable triple-negative breast cancer are eligible. Patients who need adjuvant chemotherapy after breast surgery as well as patients who need neoadjuvant chemotherapy for TNBC are eligible.
Breast Cancer
DRUG: taxane plus carboplatin|DRUG: Taxane
5-year event-free survival (EFS), time from Cycle1 Day1 to the occurrence of the following events

: loco-regional recurrence, distant recurrence, death from any cause, contralateral invasive breast cancer, second primary cancer, and cancer after surgery (not R0 resection), definitive disease progression during neoadjuvant chemotherapy, inoperable status after neoadjuvant chemotherapy, 5 year
overall survival, Time from C1D1 until death from any cause, 5 year|Distant recurrence free survival, Time from C1D1 until distant recurrence, 5 year|loco-regional recurrence free survival, Time from C1D1 until locoregional recurrence, 5 year|pathologic complete response rate, no evidence of invasive carcinoma in both breast and axillary lymph nodes, regardless of ductal carcinoma in situ (ypT0isN0), 5 year
This is a randomized, open-label, multicenter, phase III study comparing anthracyclines followed by taxane to anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer.

Patients with stage II/III operable triple-negative breast cancer are eligible. Patients who need adjuvant chemotherapy after breast surgery as well as patients who need neoadjuvant chemotherapy for TNBC are eligible.